In a notable display of confidence, two major financial institutions upgraded their ratings for Bayer AG in a single session. Barclays raised its recommendation to “Overweight,” while UBS moved to a “Buy” rating. The market responded positively, with the company’s equity advancing more than four percent.
Legal Overhang Shows Signs of Clearing
A significant factor behind the renewed optimism is the evolving landscape surrounding glyphosate litigation. Analysts now perceive the potential rewards as outweighing the risks, following preliminary court approval for a settlement worth up to $7.25 billion to resolve tens of thousands of Roundup claims. This agreement, however, is not yet final; the possibility of claimants opting out remains a concern. Furthermore, a ruling from the U.S. Supreme Court in the Durnell precedent case is anticipated by June 2026, which is expected to provide greater clarity on future liability frameworks.
Should investors sell immediately? Or is it worth buying Bayer?
Drug Pipeline Viewed as a Growth Engine
The core of the upgraded outlook rests on Bayer’s pharmaceutical development portfolio. Charles Pitman-King, an analyst at Barclays, contends that newer medications—including Kerendia, Beyonttra, and Lynkuet—are positioned to offset foreseeable revenue declines from the patent expirations of Xarelto and Eylea this year. He projects a return to mid-single-digit percentage growth starting in 2027. UBS cited encouraging Phase 3 data for the drug Finerenone as additional grounds for its rating change.
Cash Flow and Valuation Present a Mixed Picture
These positive signals are tempered by ongoing financial challenges. For 2026, Bayer is targeting an operational EBITDA of €9.6 to €10.1 billion on a currency-adjusted basis, representing essentially stable performance. However, free cash flow is forecast to be negative, largely due to approximately €5 billion in litigation-related payments. The company also plans structural cost savings of €2 billion by the end of 2026. From a technical perspective, the stock appears deeply oversold, with a Relative Strength Index (RSI) reading just below 20. This reflects the significant pressure seen in recent weeks, during which the share price declined roughly twelve percent on a monthly basis.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from March 17 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 17.
Bayer: Buy or sell? Read more here...
